Xenon Pharmaceuticals Inc. (XENE) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Xenon Pharmaceuticals Inc. (XENE:NASDAQ), powered by AI.

Current Price
$51.99
P/E Ratio
-11.9
Market Cap
4.1B
Sector
Healthcare
What is the Xenon Pharmaceuticals Inc. stock price forecast?

Xenon Pharmaceuticals Inc. is currently trading at $51.99. View real-time AI analysis on Alpha Lenz.

What is Xenon Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Xenon Pharmaceuticals Inc. on Alpha Lenz.

What is Xenon Pharmaceuticals Inc.'s P/E ratio?

Xenon Pharmaceuticals Inc.'s P/E ratio is -11.9.

Xenon Pharmaceuticals Inc.

NASDAQ · XENE
$51.99-0.41(-0.78%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Xenon Pharmaceuticals Inc.'s future dividend policy...
Alpha Chat Insight

Xenon Pharmaceuticals Inc. trades at a P/E of -11.9 (undervalued) with modest ROE of -51.8%.

Ask for details

Company Overview

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. The primary function of Xenon Pharmaceuticals is to advance its research and development pipeline of targeted treatment candidates, particularly in areas such as epilepsy and rare neurological conditions. The company is distinguished by its strong emphasis on proprietary technologies and its ability to leverage its expertise in ion channel genetics. Xenon Pharmaceuticals impacts the biotechnology sector by contributing to the understanding and treatment of neurological diseases through its scientific advancements. Based in Canada, the company collaborates with global scientific and medical communities to translate their research into clinical success. By addressing niche therapeutic areas with unmet medical needs, Xenon Pharmaceuticals plays a significant role in the biotech industry, working towards providing patients with more effective treatment options.

CEOMr. Ian C. Mortimer C.M.A., CPA, M.B.A.
SectorHealthcare
IndustryBiotechnology
Employees316

Company Statistics

FY 2025

Profile

$4.12BMarket Cap
$7.50MRevenue
0.00Shares Out
316Employees

Margins

N/AGross
-4958.33%EBITDA
-4974.27%Operating
-4598.59%Pre-Tax
-4612.13%Net

Valuation

-11.91P/E
7.08P/B
549.39EV/Sales
-10.57EV/EBITDA
-14.72P/FCF

Growth (CAGR)

-7.36%Rev 3Yr
-25.26%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-48.34%ROA
-51.76%ROE
-52.13%ROIC

Financial Health

$199.16MCash & Cash Equivalents
$-147.76MNet Debt
8.84%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Xenon Pharmaceuticals Inc. (ticker: XENE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 316 employees. Market cap is $4.1B.

The current price is $51.99 with a P/E ratio of -11.91x and P/B of 7.08x.

ROE is -51.76% and operating margin is -4974.27%. Annual revenue is $8M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Xenon Pharmaceuticals Inc. (XENE) Stock Forecast 2026 $51.99 — Price, Financials & Analyst Targets | Alpha Lenz